Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (52): 9760-9763.doi: 10.3969/j.issn.1673-8225.2011.52.016

Previous Articles     Next Articles

Celecoxib prevents against heterotopic ossification after total hip arthroplasty 

Zhao Wei-guang1, Liu Li1, Li Xiao-lei2, Liu Zhen-wu1   

  1. 1Department of Orthopaedics, 2Department of Neurology, Handan Central Hospital, Handan  056001, Hebei Province, China
  • Received:2011-09-15 Revised:2011-11-02 Online:2011-12-24 Published:2011-12-24
  • Contact: Liu Zhen-wu, Associate chief physician, Department of Orthopaedics, Handan Central Hospital, Handan 056001, Hebei Province, China
  • About author:Zhao Wei-guang★, Master, Physician, Department of Orthopaedics, Handan Central Hospital, Handan 056001, Hebei Province, China zhaoweiguang361@163.com

PDF

617

Abstract:

BACKGROUND: Currently, indomethacin is commonly used in preventing heterotopic ossification after total hip arthroplasty. However, it has serious adverse gastrointestinal reactions. While celecoxib used as COX-2 specific inhibitor has less gastrointestinal side effects in theory, but its effect on prevention of heterotopic ossification after total hip arthroplasty is still unclear.
OBJECTIVE: To explore the effect of celecoxib on preventing heterotopic ossification of total hip arthroplasty patients and provide the basis for clinical medication of patients with gastrointestinal symptoms.
METHODS: Fifty patients received total hip arthroplasty from December 2010 to May 2011 were recruited into this study. The mean age was (65.40±3.24) years old, and 19 left hips and 32 right hips were involved. The patients were divided into celecoxib group and indomethacin group randomly, and were treated with celecoxib of 200 mg/d and indomethacin of 75 mg/d for 6 weeks respectively.
RESULTS AND CONCLUSION: The incidence of heterotopic ossification was 12.0% in the celecoxib group and 16.0% in the indomethacin group, and there was no significant difference between them (P > 0.05). Harris hip function scores showed the excellent and good rate was 88.0% in the celecoxib group and 76.0% in the indomethacin group, and the difference had no significance (P > 0.05). The incidences of gastrointestinal side effects in the celecoxib group and indomethacin group were 16.0% and 36.0% respectively, and the difference was significant (P=0.039). Chi-square test showed the data about adverse reaction between the two was distinctly different (P=0.039). It is indicated that the celecoxib can be used in preventing heterotopic ossification of total hip arthroplasty patients with less gastrointestinal side effects.

CLC Number: